HORuS2050

Hyperbaric Oxygen Therapy Cohort and Biobank Study

Turning fragmented experience into shared evidence
Preparing the study overview…
This will only take a moment.
Loading the study…
Read the full study Contact the study team
HORUS2050

HORuS2050

A Multicentre Prospective Cohort and Biobank Study of Hyperbaric Oxygen Therapy Outcomes

M. Starnawski1, L. Strasser1, F. Cuntze1, A. Kjellberg2,1

1Nubiss GmbH, Berlin, Germany  ·  2Karolinska Institutet, Department of Physiology and Pharmacology, Stockholm, Sweden

01 · Why HORUS2050?

Turning fragmented experience into shared evidence

HBOT is of broad clinical interest, but evidence remains dispersed across small studies, different treatment protocols and isolated patient groups.

130+Indications for which HBOT has historically been explored.
10–15Indications widely accepted by international hyperbaric medicine societies.
The HBOT evidence gap One hundred and thirty bubbles, one for each condition hyperbaric oxygen therapy has been explored for. Fifteen in the centre of the top row are highlighted: ten solid and five outlined, representing the ten to fifteen indications widely accepted by international hyperbaric medicine societies. The remaining one hundred and fifteen fade away beneath them. 10–15 WIDELY ACCEPTED
Each bubble is one condition HBOT has been explored for.

Swipe to see the whole field.

InclusionAll individuals accepted for HBOT at a participating centre — at any pressure, gas mix or indication — who provide informed consent. Healthy volunteers are also eligible, forming a propensity-matched reference cohort.
ExclusionInability to comply with study procedures or informed consent (e.g. cognitive impairment or language barriers).

02 · Overall aim

HORUS2050 will create a standardised multicentre evidence base describing:

  • who receives HBOT and why
  • chambers and protocols used
  • changes in participant-reported outcomes
  • benefits, limitations and potential harms
  • differences between cohorts and controls
  • hypotheses for future interventional studies

Large datasets and routine-care biomarkers may later support exploratory predictive modelling. No predictive model is used for current clinical decision-making.

HBO₂ — hyperbaric oxygen, unchanged by the study The letters HBO with a subscript 2, the UHMS abbreviation for hyperbaric oxygen. Oxygen bubbles rise from the 2. HBO2
Chamber, pressure and gas — unchanged

03 · The network

A study built across borders

  • 5Countries expected
  • Q4 2026First participant
  • 100–300Participants in year one
The HORuS2050 site network A map reaching from the eastern United States across Europe to India. Centres are expected to be live in Austria, Ireland, Germany, Poland and Sweden. Potential centres are marked in France, Spain, Italy and Finland, and dashed arcs reach out to the United States and India. USA INDIA IRELANDGERMANYSWEDENPOLANDAUSTRIA
  • Centres expected at launch
  • Potential centres
  • Expanding towards the USA and India

Swipe to see the whole network.

Join the registry

Contact the study team

Recruiting founding centres now. First participant expected Q4 2026 — onboarding is open.

04 · How HORUS2050 works

From enrolment to longitudinal analysis

PARTICIPANTSPatients · Healthy
participants · Controls
BASELINEMedical data
+ PROMs
USUAL CARENo study
intervention
FOLLOW-UPPROMs
+ outcomes
ANALYSISLongitudinal
cohort analysis

Parallel entry routes

  • Retrospectivedata capture
  • Relevant cohortanalysis
  • Prospectiveenrolment

No study procedure influences clinical decision-making, treatment selection, pressure, gas mixture, dosing, timing or standard of care. Research data only.

05 · Data contributing to the registry

Five streams, one dataset

CLINICALDiagnoses · symptoms
medical history
HBOTChamber · pressure
gas · sessions
PROMsQuality of life
symptoms · function
WEARABLESParticipant-generated
longitudinal data
BIOMARKERSRoutine care only
where locally collected

Who may contribute?

  • PATIENTS RECEIVING HBOTAccepted by a participating centre for any locally accepted condition, indication or objective.
  • HEALTHY PARTICIPANTSReceiving HBOT for preventive-health, performance or another locally accepted objective.
  • COMPARATOR PARTICIPANTSSelected individuals without HBOT exposure for control cohorts and matched analyses.

Previously treated participants may contribute through retrospective data entry where appropriate.

UNIFIED LONGITUDINAL RESEARCH DATASET

06 · Study horizon

Continuous evidence generation beyond 2050
  1. Q4 2026Expected first participant
  2. YEAR ONEEstimated 100–300 participants
  3. MULTICENTRE GROWTHRolling analyses
  4. LONG-TERM FOLLOW-UPNew cohorts and hypotheses
  5. 2050+Continuous evidence generation